My understanding is that maraviroc blocks everything from binding to CCR5, whereas leronlimab allows for normal functions and other chemokines that bind outside of the 108% of the CCR5 receptor that leronlimab blocks. I'm not sure that there has been enough research done yet to compare all the differences between blocking a precise portion of CCR5 vs blocking the entire receptor.

The one thing we know from the trials to date is maraviroc has toxicity and develops resistance whereas leronlimab has negligible toxicity, no resistance or harmful drug-to-drug reactions. Both may help with COVID and long haulers if BPs research proves out.